(Total Views: 500)
Posted On: 10/31/2020 4:43:37 PM
Post# of 72440
Reading the preprint here's another highlight from page 7:
"To independently assess the impact of brilacidin on the virion and thus add support to the role of brilacidin as an inhibitor of viral entry, a direct virus inhibition assay was conducted akin to virus neutralization observed in the presence of antibodies. To that end, SARS-CoV-2 inoculum was incubated with brilacidin at 10µM concentration for 1 hour after which the treated inoculum
was used to infect Vero cells. In this experiment, the cells were not pre-treated with the inhibitor (brilacidin) prior to the infection. After 1 hour of infection, the inoculum was removed and replaced with fresh media without any inhibitor and the cells were maintained in inhibitor-free media for 24 hours. The infectious virus titer in the supernatant was quantified by plaque assay, which revealed a dramatic 90% reduction of virus titer (Figure 2E, indicated as [entry]). This
inhibition was approximately 25% higher than that observed when the cells were pre- and posttreated with brilacidin concomitantly (Figure 2E) supporting the concept that brilacidin has a direct inhibitory effect on the virus in a manner similar to the neutralization of antibodies, potentially by disrupting viral integrity and thus impairing the virion’s ability to complete the viral entry process"
"To independently assess the impact of brilacidin on the virion and thus add support to the role of brilacidin as an inhibitor of viral entry, a direct virus inhibition assay was conducted akin to virus neutralization observed in the presence of antibodies. To that end, SARS-CoV-2 inoculum was incubated with brilacidin at 10µM concentration for 1 hour after which the treated inoculum
was used to infect Vero cells. In this experiment, the cells were not pre-treated with the inhibitor (brilacidin) prior to the infection. After 1 hour of infection, the inoculum was removed and replaced with fresh media without any inhibitor and the cells were maintained in inhibitor-free media for 24 hours. The infectious virus titer in the supernatant was quantified by plaque assay, which revealed a dramatic 90% reduction of virus titer (Figure 2E, indicated as [entry]). This
inhibition was approximately 25% higher than that observed when the cells were pre- and posttreated with brilacidin concomitantly (Figure 2E) supporting the concept that brilacidin has a direct inhibitory effect on the virus in a manner similar to the neutralization of antibodies, potentially by disrupting viral integrity and thus impairing the virion’s ability to complete the viral entry process"
(2)
(0)Scroll down for more posts ▼
